Correlation of Neutrophil to Lymphocyte Ratio with Interleukin-10 in Diagnosis and Monitoring of Coronavirus Disease-19 Patients
DOI:
https://doi.org/10.3889/oamjms.2022.7721Keywords:
COVID-19, NLR, IL-10Abstract
BACKGROUND: The enforcement of diagnosis and monitoring of therapy success in SARS-Cov-2 infection, which causes COVID-19 disease, necessitates laboratory tests that may assess and identify patients prior to developing critical circumstances requiring additional treatment. The Neutrophil to Lymphocyte Ratio (NLR) and Interleukin-10 (IL-10) testing are two laboratory procedures used.
AIM: This study aims to determine the correlation between NLR and Interleukin-10 (IL-10) in diagnosing and monitoring COVID-19 patients.
METHODS: An observational analytic cross-sectional design enrolled about 73 COVID-19 patients who met the inclusion criteria and were willing to participate in the study. The levels of NLR and IL-10 were assessed by Sysmex XS-800i Automated Hematology Analyzer and sandwich ELISA methods. Data were analyzed using SPSS version 17 for Windows.
RESULTS: A median of NLR values was 4.02 (1.24-47.89), following IL-10 concentration was 1.870 (0.110–33.368) pg/mL. There was a significant difference in NLR values between critical and non-critical categories (p = 0.000), geriatric and non-geriatric groups (p = 0.006), as well as in groups with comorbid and without comorbidities (p = 0.006). Meanwhile, a significant difference in IL-10 levels was only found between critical and non-critical categories (p = 0.000). There was a moderately significant positive correlation between NLR and IL-10 in COVID-19 patients (r = 0.411; p = 0.000).
CONCLUSION: There is a significant positive correlation between NLR values and IL-10 levels in COVID-19 patients.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Baloch S, Baloch MA, Zheng T, Pei X. The Coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med. 2020;250(4):271-8. https://doi.org/10.1620/tjem.250.271 PMid:32321874 DOI: https://doi.org/10.1620/tjem.250.271
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-54. https://doi.org/10.1038/s41579-020-00459-7 PMid:33024307 DOI: https://doi.org/10.1038/s41579-020-00459-7
Liu YP, Li GM, He J, Liu Y, Li M, Zhang R, et al. Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: A retrospective cohort study. Ann Transl Med. 2020;8(10):635. https://doi.org/10.21037/atm-20-2372 PMid:32566572 DOI: https://doi.org/10.21037/atm-20-2372
Prabawa IP, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AA, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pac J Cancer Prev. 2019;20(3):863-8. https://doi.org/10.31557/APJCP.2019.20.3.863 PMid:30912405 DOI: https://doi.org/10.31557/APJCP.2019.20.3.863
Wiranata S, Anjani IA, Saputra IP, Sadvika IG, Prabawa IP, Supadmanaba IG, et al. Pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as a stage determination in breast cancer. Open Access Maced J Med Sci. 2020;8:1058-63. DOI: https://doi.org/10.3889/oamjms.2020.5336
Ding X, Yu Y, Lu B, Huo J, Chen M, Kang Y, et al. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019. Clin Chem Lab Med. 2020;58(8):1365-71. https://doi.org/10.1515/cclm-2020-0411 PMid:32441666 DOI: https://doi.org/10.1515/cclm-2020-0411
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5 PMid:31986264 DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62-75. https://doi.org/10.1016/j.cytogfr.2020.06.001 PMid:32513566 DOI: https://doi.org/10.1016/j.cytogfr.2020.06.001
Lu L, Zhang H, Dauphars DJ, He YW. A potential role of interleukin 10 in COVID-19 pathogenesis. Trends Immunol. 2021;42(1):3-5. https://doi.org/10.1016/j.it.2020.10.012 PMid:33214057 DOI: https://doi.org/10.1016/j.it.2020.10.012
Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int J Infect Dis. 2020;96:131-5. https://doi.org/10.1016/j.ijid.2020.04.086 PMid:32376308 DOI: https://doi.org/10.1016/j.ijid.2020.04.086
Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541-3. DOI: https://doi.org/10.1038/s41423-020-0401-3
Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123-30. https://doi.org/10.1080/22221751.2020.1770129 PMid:32475230 DOI: https://doi.org/10.1080/22221751.2020.1770129
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. https://doi.org/10.3389/fimmu.2020.01446 PMid:32612617 DOI: https://doi.org/10.3389/fimmu.2020.01446
Lindner HA, Velásquez SY, Thiel M, Kirschning T. Lung protection vs. Infection resolution: Interleukin 10 suspected of double-dealing in COVID-19. Front Immunol. 2021;12:602130. https://doi.org/10.3389/fimmu.2021.602130 PMid:33746948 DOI: https://doi.org/10.3389/fimmu.2021.602130
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Sianny Herawati, Yenny Kandarini, Ni Kadek Mulyantari, Putu Yuda Prabawa (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
